Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BiomX (PHGE)
NYSE MKT:PHGE
BiomX (PHGE) Stock Price & Analysis
396 Followers
PHGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.19 - $0.86
Previous Close$0.34
Volume92.06K
Average Volume (3M)182.80K
Market Cap
$23.82M
Enterprise Value$17.58M
Total Cash (Recent Filing)$22.45M
Total Debt (Recent Filing)$16.21M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Aug 14, 2024EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding69,806,440
10 Day Avg. Volume84,587
30 Day Avg. Volume182,799
Standard Deviation0.26
R-Squared0.07
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)2.85
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$2.17Price Target Upside517.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
BiomX News
Bulls Say, Bears Say
Bulls Say
AcquisitionBiomX's acquisition of Adaptive Phage Therapeutics brings personalized phage treatment BX211, currently in a Phase 2 study, which may offer a new treatment for diabetic foot osteomyelitis associated with S. aureus.
Clinical TrialsImpressive data from Phase 1b/2a trials of BX004 showed potential for treatment of cystic fibrosis patients.
Financial PerformanceBiomX reported better than expected 4Q'23 financials with a smaller EPS loss than consensus estimates.
Bears Say
EarningsBiomX announced 1Q24 financial results, posting EPS of ($0.28) compared with analyst estimate of ($0.07); the difference came from warrant accounting.
FundingDespite completing the 2024 March PIPE, management believes the company will likely need additional funding in the future to support its operating expenses and capital requirements.
Price TargetThe dilution led to our reduced price target of $2 from $4.
---
Ownership Overview
50.94% Insiders
0.07% Mutual Funds
35.03% Other Institutional Investors
13.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PHGE FAQ
What was BiomX’s price range in the past 12 months?
BiomX lowest stock price was $0.19 and its highest was $0.85 in the past 12 months.
What is BiomX’s market cap?
Currently, no data Available
When is BiomX’s upcoming earnings report date?
BiomX’s upcoming earnings report date is Aug 14, 2024 which is in 42 days.
How were BiomX’s earnings last quarter?
Currently, no data Available
Is BiomX overvalued?
According to Wall Street analysts BiomX’s price is currently Undervalued.
Does BiomX pay dividends?
BiomX does not currently pay dividends.
What is BiomX’s EPS estimate?
BiomX’s EPS estimate is -$0.09.
How many shares outstanding does BiomX have?
BiomX has 69,806,440 shares outstanding.
What happened to BiomX’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BiomX?
Among the largest hedge funds holding BiomX’s share is Deerfield Management Company, LP. It holds BiomX’s shares valued at 3M.
---
BiomX Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.17 (517.18% Upside)
$2.17 (517.18% Upside)
Hedge Fund Trend
Increased
By 6.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.27%
12-Months-Change
Fundamentals
Return on Equity
-190.33%
Trailing 12-Months
Asset Growth
97.08%
Trailing 12-Months
Company Description
BiomX
BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.
---
PHGE Earnings Call
Q1 2024
0:00 / 0:00
---
PHGE Stock 12 Month Forecast
Average Price Target
$2.17
▲(517.18% Upside)
Technical Analysis
Best Analysts Covering PHGE
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
+0.35%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of +0.35% per trade.
---